IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-28 (managedhealthcareexecutive.com)
Luke Greenwalt, MBA, on the Current Market Conditions for New Drug Launches | Asembia's AXS25 Summit
The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark during their first year on the market than in the past.
Read more
2025-04-07 (drugstorenews.com)
IQVIA 2025 report sizes up trends in new drug launches, other areas |
Biopharma funding reached $102 billion in 2024 — a substantial increase on the 2023 figure of $71 billion.
Read more
2025-03-20 (hankyung.com)
Celltrion, Order in Italy, Stekima |
Celltrion is expanding its bidding results in Italy, one of the five major European countries, with autoimmune disease treatment, and Stecima, which was released in January of this year, opened the bidding performance in two months. The Celltrion Italian subsidiary has recently succeeded in winning Stekima orders from the Ustekima bids held in four state governments, Piemonte, Valle D'Aosta, Liguria, and Sardegna. The combined size of the region is about 10%of the Italian Ustecinumab market, which will be supplied by Stekima by 2028.In the bidding of the adalimumab bids in Lazio, Lombardia, and Umbria, of the 21 Italian governments. 'Uflyma' was a successful bid. Starting this month, Lazio and Lombardia will be supplied with Ulflymas for the next three years and Umbria for two years, according to IQVIA, a pharmaceutical market research firm, with a 43%share in Italy as of the third quarter of last year, continuing the first place after the last quarter.
Read more
2025-03-04 (globenewswire.com)
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating...
Read more
2025-01-18 (mexicobusiness.news)
AWS Bets US$5 Billion on Mexico's Digital Future: AI Week
This week, AWS opens a new region in Mexico, Gen AI fuels chip demand, and Nvidia partners with IQVIA to advance AI in healthcare.
Read more
2025-01-13 (stocktitan.net)
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Verastem strengthens financial position with $150M credit facility and strategic IQVIA partnership to support 2025 launch of avutometinib for ovarian cancer treatment.
Read more
2024-10-15 (financialexpress.com)
Lupin launches first generic formulation of Abbie’s drug to treat eye disorder
Pred Forte had estimated annual sales of USD 198 million in the U.S., as per IQVIA MAT August 2024.
Read more
2024-08-21 (direitoenegocios.com)
Farmácia SemperFort, from the Pereira Group, accelerates expansion with the opening of new stores and job opportunities
The pharmacy chain plans openings in three states and aims to surpass 50 units in five years
Read more
2024-05-07 (financialexpress.com)
Dr. Reddy's Q4FY24 Results: Consumer Health segment to drive growth of India Business; To focus on M&A opportunities in FY25 - Healthcare News | The Financial Express
Dr. Reddy's Q4FY24 Results: During the quarter, the company launched three new brands in India, taking the annual total to 13.
Read more
2024-03-27 (livemint.com)
Dr. Reddy’s to promote and distribute Sanofi’s vaccine brands
The tie-up gives DRL a stronger portfolio and takes it to second place among vaccine players in India.
Read more
2024-02-14 (reuters.com)
IQVIA quarterly results beat estimates on strong demand for research services
IQVIA Holdings beat Wall Street estimates for fourth-quarter sales and profit on Wednesday, on the back of strong demand for its drug research and development services.
Read more
2023-11-30 (wiadomoscikosmetyczne.pl)
Six new Hebe drugstores within a month
The Hebe chain has opened another drugstore. This time in Ostróda. This is the sixth new store of the chain opened in November this year.
Read more